“It’s encouraging to see the positive results in these studies correcting the most common CF gene mutation, F508del, and we hope future research could lead to the development of genetic therapy ...

Alyftek is approved for use with CF patients aged six years or older who have at least one F508del mutation or another CFTR mutation responsive to the therapy. It builds on the success of Trikafta ...